Kurzrock, Razelle <br/><br/>
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.  [electronic resource] 

 -  Cancer  Dec 2012 
 - 6144-51 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0142 
<br/><br/><label>Standard No.: </label>10.1002/cncr.27647  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Camptothecin--analogs & derivatives<br/>DNA, Neoplasm--genetics<br/>Female<br/>Follow-Up Studies<br/>Glucuronosyltransferase--blood<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms--drug therapy<br/>Polyethylene Glycols--pharmacokinetics<br/>Polymerase Chain Reaction<br/>Polymorphism, Genetic--genetics<br/>Prognosis<br/>Safety<br/>Tissue Distribution